METABOLIC

CARDIO

CARDIO METABOLIC

Cardiovascular and Metabolic disease is a major burden worldwide. It has been estimated that deaths due to heart disease will increase by 50% in developed countries and by 100% in low and middle income countries by 2020. However, there has been a decline in all phases of cardiovascular drug development in the past decade. This can be attributed to several factors: increased regulatory demands for more and more data; patient recruitment; complexity of protocols; and studies are long and costly – especially if the results do not result in any new treatments or have a negative impact on the subjects. It is clear, therefore, a new way of conducting trials in a cost-effective and more streamlined manner needs to be found.

THE CHALLENGES

  • Large number of subjects needed and target population is decreasing due stringent inclusion / exclusion requirements
  • Trials are complex and costly – it can take 10 years and an investment of $4 Billion to bring one new novel drug to market
  • Regulatory agencies are demanding more and more data, with an emphasis on clinical outcome, which increases the complexity of the protocols

OUR SOLUTION

  • Global scientific networks and peer-to-peer leadership model greatly increase recruitment of the right subjects at the right locations
  • Operational excellence ensures faster start-up and trial management
  • Deep in-house Cardiovascular expertise and access to academic institutions that aid in protocol development
  • Comprehensive understanding of the regulatory environment

HIGHLIGHTED TRIALS

7 TRIALS
1785 SITES
44496 PATIENTS

ADVANCE

16 Sides
26 Patients
Finished
More information

ALTITUDE

45 Sites

8600 Patients

Finished

Alecardio

586 Sites

7000 Patients

Finished

DISCOVER

56 Sites

172 Patients

Finished

HAT

150 Sites

698 Patients

Finished

SPIRE I

481 Sites

4300 Patients

Finished

SPIRE II

451 Sites

2300 Patients

Finished

SCIENTISTS

A key strength of Julius Clinical is the academic expertise and integrity of our scientific team. Our scientific leaders have broad experience on study committees and are able, through their contacts, to bring together and work effectively with international networks of thought leaders. Our scientific officers related to the therapeutic expertise Cardio Metabolic, are:

PROF. DIEDERICK E. GROBBEE

PROF. DIEDERICK E. GROBBEE

Chief Scientific Officer

Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical, and a Professor of Clinical Epidemiology at the University Medical Center (UMC) Utrecht, the Netherlands. His other current roles include Chair of the focus area Circulatory Health at the UMCU.

DR. MARCO ALINGS

DR. MARCO ALINGS

Cardiologist / electrophysiologist

Marco Alings, MD, PhD, FESC, is a practicing cardiologist / electrophysiologist and Director of the cardiology training program at the Amphia Ziekenhuis, Breda, the Netherlands.

PROF. JOOST HOEKSTRA

PROF. JOOST HOEKSTRA

Clinical diabetology specialist

Prof. dr. Joost Hoekstra’s scientific expertise is focused on clinical diabetology. In this broad area he supported some 20 PhD students and gave numerous lectures, primarily within the Netherlands.

NETWORKS

Clinical Investigator Networks are a vital element in both academic and clinical research settings. Among peers in the scientific community, investigators communicate and collaborate directly, contributing to the advance of the study imperatives. For this reason, within the clinical research setting, advantages are gained when coordinated research networks are maintained and managed. Networks that are related to the therapeutic expertise Cardio Metabolic, are:

NASH Clinical was founded in Zeist, the Netherlands in December 2018 by Julius Clinical, an Academic Research Organization, as a fully independent research network with the mission to decrease the global NASH problems. The founding members, who share many values professionally, had already been connected through research, education or other network activities.

NASH Clinical is a global network of clinicians / investigators. Participating clinicians are: endocrinologists, gastro-enterologists, diabetologists and general internists. There are connections with a dozen of hospitals in the Netherlands and many hospitals worldwide. Read more on the NASH Clinical website

See all our networks.